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Neuropsychological dysfunction associated with cancer and cancer treatment is a growing concern. Methodological limitations
permeate the corpus of research in this area and have limited our understanding of the multifactorial nature of this process. The
following review provides a summary of the current state of knowledge and highlights future directions.
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While it is generally recognised that central nervous system (CNS)
cancer and many of the therapeutic modalities used to treat cancer
can cause alterations in neurocognitive function, our knowledge
about the nature, severity, and course of neurocognitive dysfunc-
tion is limited. Traditionally, treatment outcome has focused on
the length of survival and neurological or physiological changes
such as peripheral neuropathy, ototoxicity, or encephalopathy
rather than indices of ‘quality of life’, such as neurocognitive
function. Neurocognitive function has been demonstrated to be a
sensitive, viable, and important end point that measures clinical
benefit on patient functioning that is not adequately captured in
clinical trials with measures of overall survival or patient
performance status (Meyers and Hess, 2003). In the United States,
government agencies have emphasised the need to develop and
utilise multifaceted end points in clinical trials that will measure
disease-related symptoms and/or quality of life. In addition to
monitoring neurotoxicity, neurocognitive function has been
demonstrated to be a sensitive predictor of patient survival
(Meyers et al, 2000b), and change in neurocognitive function has
been found to precede MRI evidence of tumour recurrence in
glioma patients (Armstrong et al, 2003; Meyers and Hess, 2003).
Such findings have prompted the incorporation of neuropsycho-
logical evaluations in the clinical care of cancer patients (Meyers,
1997).
Advances in the successful treatment of cancer have been
achieved largely by an increased aggressiveness of therapy, which
now generally combines surgery, radiation, cytotoxic drugs, and
immunotherapy. Unfortunately, cancer treatments are not highly
specific and place normal tissues and organs at risk. The CNS is
vulnerable to many types of cancer treatments, both systemic and
those directed against CNS tumours. In addition, many adjuvant
medications necessary for the treatment of medical complications
also affect CNS function (e.g. steroids, antiepileptics, immunosup-
pressive agents, and drugs used for pain, nausea, and infection).
There is a burgeoning literature on the neurocognitive effects of
cancer treatment. Unfortunately, few methodologically rigorous
studies exist to guide clinical practice. Most studies are retro-
spective, fail to incorporate assessments of pretreatment neuro-
cognitive and neurobehavioural function, consist of small and
heterogeneous samples, lack appropriate control groups, and
suffer from poor measurement selection. Owing to the state of the
literature, we will first describe principles that we believe underlie
specific areas of practice and research. The empirical findings that
support these principles will then be reviewed to provide a
summary of the current knowledge with regard to neurocognitive
dysfunction. These principles provide clinicians and researchers
with a starting point from which further refinement of these
concepts are expected. Finally, we will highlight key issues that
may improve future research and patient care.
RADIOTHERAPY
Principle: Radiotherapy, whether incidental or directed principally
at brain tissue, produces a predictable pattern of neurocognitive and
neurobehavioural alterations. The development of these features
and the time course are strongly related to treatment parameters,
concomitant adjuvant therapy, and patient characteristics.
The adverse effects of radiation to the brain, both as primary
CNS therapy and prophylactic treatment, have been previously
reviewed in detail (Crossen et al, 1994; Keime-Guibert et al, 1998).
The development of neurologic and/or neuropsychological dys-
function is often the greatest dose-limiting factor of radiotherapy
(XRT). Pathologically, autopsy reports have suggested that radio-
therapy primarily affects the white matter tracts and cerebral
vasculature of the brain via two mechanisms: (1) damaging
oligodendrocytes, thereby creating axonal demyelination and (2)
disrupting vascular endothelial cells contributing to coagulative
necrosis, vessel wall thickening, and focal mineralisation. Owing to
the relative density of white matter in frontal and subcortical areas,
cognitive impairments consistent with frontal network systems
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www.bjcancer.comdysfunction are common, including impaired processing speed,
attention (e.g. working memory), learning efficiency and memory
retrieval, executive function (e.g. mental flexibility), and often
bilateral decline in motor function (e.g. fine motor dexterity)
(Crossen et al, 1994; Gregor et al, 1996; Meyers et al, 2000a).
The occurrence of radiation encephalopathy has been most well
studied in patients receiving either conventional, hyperfractio-
nated, or whole brain radiotherapy. The effects of stereotactic
radiosurgery and intensity modulated radiotherapy are currently
unknown. Radiation encephalopathy has been separated into three
stages: acute reaction, early-delayed reaction, and late-delayed
reaction (Sheline, 1977). Radiation to the brain is rarely
administered without systemic chemotherapy for the primary
disease, and it is often not possible to separate the adverse effects
of radiation from chemotherapy. The toxicity of radiation is likely
synergistic with concurrent chemotherapy (Crossen et al, 1994).
Thus, discussion of treatment effects will assume that the toxicity
is caused primarily by cranial irradiation, although the possible
synergistic toxicity of multimodality therapy is yet to be fully
delineated. Risk factors for developing XRT-induced cognitive
dysfunction and radiation necrosis include age 460 years old,
42Gy dose per fraction, higher total dose, greater volume of brain
irradiated, hyperfractionated schedules, shorter overall treatment
time, concomitant or subsequent use of chemotherapy, and
presence of comorbid vascular risk factors (e.g. diabetes) (Crossen
et al, 1994; Lee et al, 2002).
A transient acute encephalopathy, resulting in generalised
neurocognitive dysfunction, has been described, which is thought
to be related to breakdown of the blood–brain barrier and is
occasionally associated with focal neurologic signs, suggesting
recurrent neoplasm (Crossen et al, 1994). However, the incidence
of early-delayed effects of radiotherapy has been reduced with
corticosteroid therapy. Studies of the neurocognitive functioning
of patients surviving more than a year postradiotherapy have
yielded conflicting results. Meyers et al (2000a) reported on a
cohort of patients who received paranasal sinus radiation between
20 months and 20 years prior. Neuropsychological test results
revealed 80% of the patients exhibited impaired memory,
approximately 33% manifested slowed visuomotor speed, execu-
tive dysfunction, and poor fine motor dexterity. Others have failed
to find significant late-delayed neurocognitive dysfunction as a
result of radiotherapy (Vigliani et al, 1996; Torres et al, 2003).
Differences in reported radiotherapy-associated cognitive dysfunc-
tion (incidence estimates that vary from 0 to 86%) may in part be
related to differences in treatment variables, study methodology,
and the disease that is being treated.
CHEMOTHERAPY
Principle: Adjuvant chemotherapy has been associated with
decrements of neurocognitive and neurobehavioural functioning
during the acute phase, but the persistence of these sequelae remain
controversial.
Although chemotherapy has proven beneficial in the treatment
of a variety of malignancies, these treatments may have both acute
and persistent adverse effects on the nervous system (Keime-
Guibert et al, 1998). A variety of nonspecific neurological
complications associated with chemotherapy have been described,
including: (1) an acute encephalopathy characterised by a
confusional state, insomnia, and often agitation, which is
commonly believed to resolve off treatment; (2) chronic encepha-
lopathy characterised by cognitive dysfunction consistent with a
‘subcortical dementia’, incontinence, and gait disturbance; (3)
stroke-like episodes associated with transient motor impairments;
(4) a cerebellar syndrome with symptoms ranging from ataxia to a
pancerebellar syndrome; and (5) a variety of peripheral neuro-
pathies.
Certain agents are known to be particularly neurotoxic. For
instance, methotrexate and 5-FU can cause diffuse white matter
changes on neuroimaging. Other agents have been found to affect
specific neuroanatomical structures preferentially. For example,
CI-980 selectively affects memory by binding to tubulin at the col-
chicine binding site and selectively blocking choline acetyltrans-
ferase in the hippocampus and basal forebrain (Meyers et al, 1997).
Reports of neurophysiologic and functional neuroimaging
abnormalities in breast cancer survivors previously treated with
adjuvant chemotherapy have also been observed. However, the
relationship between these indices of brain function and neuro-
cognitive function is not one-to-one. Schagen et al (2001)
examined event-related potentials, quantitative electroencephalo-
graphy, and neurocognitive function approximately 2 years after
chemotherapy in women with breast cancer who received high,
standard, or no chemotherapy. They found asymmetry of the alpha
rhythm in a subset of the patients who previously received
chemotherapy that was not associated with neurocognitive test
results or emotional distress. Silverman et al (2003) examined the
relationship between regional cerebral metabolism in breast cancer
survivors. Women who had previously received chemotherapy
alone evidenced hypometabolism in the superior frontal gyrus of
the dorsolateral prefrontal cortex as well as Broca’s area and its
homologous counterpart in the nondominant hemisphere. Further,
women who received tamoxifen (TAM) in addition to chemother-
apy evidenced even greater hypometabolism.
A recent meta-analysis examining the neurocognitive sequelae
of chemotherapy in adults reported that compared to normative
data, control samples, or baseline test performance, patients
receiving adjuvant chemotherapy experienced declines in six out
of seven neurocognitive domains evaluated (i.e. attention, proces-
sing speed, verbal memory, visuospatial, executive and motor
function). Memory and executive function reached statistical
significance and demonstrated a rather large effect size (Cohen’s
d approximately 0.9). Motor function exhibited a smaller effect size
(approximately 0.5), but also reached statistical significance.
Importantly, when only studies that used longitudinal designs
incorporating baseline evaluations were examined, none of the
cognitive domains reached significance and all demonstrated only
modest effect sizes (Anderson-Hanley et al, 2003).
Longitudinal investigations that measure patient’s baseline
neurocognitive and neurobehavioural function prior to adjuvant
therapy are required to measure idiographic change in function
and to parse out neurocognitive impairment caused by the disease
from that caused by the treatment. For example, Meyers et al
(1995a) demonstrated that a 70–80% of patients with small-cell
lung cancer have memory deficits, 38% have deficits in executive
functions, and 33% have impaired motor coordination before
treatment is initiated.
Several centres (McAllister et al, 2000; Fliessbach et al, 2003)
have demonstrated the ability to deliver potentially neurotoxic
therapies without inducing neurocognitive dysfunction. These
prospectively designed trials of treatment protocols involving
intravenous, intra-arterial, or intraventricular multiagent che-
motherapy with blood–brain barrier disruption for the treatment
of primary CNS lymphoma reported no significant neurocognitive
dysfunction in patients who achieve a durable remission 1 year
after treatment. Despite limitations in our understanding of
chemotherapy-related neurotoxicity, there has been growing
concern that subgroups of patients develop iatrogenically pro-
duced neurocognitive dysfunction that can be disabling in severity.
BIOIMMUNOTHERAPY
Priniciple: Biologic response modifiers are frequently associated
with both acute neurobehavioural and neurocognitive alterations.
Exogenous treatment with proinflammatory cytokines contributes
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tary–adrenal axis endocrine function, and secondary messengers.
However, the persistence of these untoward effects and the efficacy
of treatments that limit or prevent these effects are poorly
understood.
Proinflammatory cytokines have been reported to have both
direct and indirect effects on CNS function through the alteration
of neurotransmitters, neuroendocrine function, and induction of
secondary cytokine activity. These cascades produce a host of
neurobehavioural sequelae that have been termed ‘sickness
behaviour’ (Kelley et al, 2003). Symptoms of sickness behaviour
include fever, weakness, malaise, listlessness, and concentration
difficulties. In addition, more than 50% of patients receiving
cytokine therapy have documented neurocognitive impairments
(Meyers and Abbruzzese, 1992). For a review of these agents, their
mechanisms of action, and potential treatment strategies refer to
Meyers and Valentine (1995b) and Trask et al (2000).
Patients who manifest neurotoxicity subsequent to endogenous
administration of cytokines develop neurocognitive deficits that
are consistent with frontal network systems dysfunction including
diminished information processing speed and simple reaction
time, attentional and executive dysfunction, reduced learning and
memory, impaired fine motor dexterity, and neurobehavioural
sequelae including ‘sickness behaviour’, depression, and anxiety
(Valentine et al, 1998; Trask et al, 2000). Investigations utilising
functional neuroimaging have demonstrated abnormalities in
frontal regions that parallel the neurocognitive findings (Meyers
et al, 1994; Juengling et al, 2000).
The neurovegetative and somatic symptoms associated with
IFN-a neurotoxicity have been reported to occur within the first 2
weeks of treatment, whereas the cognitive and mood symptoms
often develop within 8–12 weeks after initiating treatment
(Capuron et al, 2001). This observation is consistent with other
reports that the length of treatment, dose, and route of
administration appear to be key factors related to the development
of neurotoxicity (Meyers, 1997). Although these symptoms may
persist for a small subgroup, most can be successfully palliated
with prophylactic or symptomatic antidepressant therapy for
neurobehavioural symptoms (Musselman et al, 2001), stimulant
therapy for fatigue and neurobehavioural slowing, and opiate
antagonist therapy for cognitive disorders (Valentine et al, 1998).
HORMONAL THERAPY
Principle: Abrupt alteration of an individual’s hormonal milieu has
been associated with neurocognitive and neurobehavioural impair-
ments. The effects of more insidious and less direct hormonal
alterations are largely unknown.
Oestrogen receptors have been discovered in many areas of the
brain important for cognitive functioning including the hypotha-
lamus, anterior pituitary, amygdala, and CA1 of the hippocampus
(McEwen and Alves, 1999). Human and animal studies (Yaffe et al,
1998) have elucidated several possible mechanisms through which
oestrogen affects neurocognitive and neurobehavioural function
including: (1) increasing cholinergic activity through its actions on
choline acetyltransferase; (2) maintenance of dendritic spine
density on CA1 pyramidal cells of the hippocampus; (3) facilitating
induction of long-term potentiation in the hippocampus; (4)
increasing serotonergic and cholinergic activity, thereby main-
taining neural circuitry; (5) altering lipoprotein; and (6) decreasing
the risk of cerebral ischaemia.
The effects of hormonal challenges in women (e.g. antioestro-
gens) have been examined with both neuroimaging (Berman et al,
1997) and neurocognitive probes (Varney et al, 1993, Rich and
Maki, 1999). In summary, a pattern of relative hypometabolism in
prefrontal cortex has been demonstrated with PET, and neuro-
cognitive impairments in memory, executive function, and motor
coordination have been reported. The severity of these impair-
ments varies, but has occasionally been reported to result in
impairments of daily living and vocational function.
Tamoxifen is a widely used selective oestrogen receptor
modulator (SERM) for the treatment of breast cancer. It is
estimated that approximately 11% of women will develop breast
cancer in their lifetime. Moreover, in the United States, it is
estimated that based on year 2000 census data more than 2 million
women could benefit from prophylactic use of TAM (Freedman
et al, 2003), highlighting the importance of understanding the
potential neurocognitive side effects of this agent. TAM is known
to have both agonist and antagonist effects in the periphery and in
the brain (McKenna et al, 1992). It has also been reported to
influence the production of proinflammatory cytokines (IL-1, IL-6,
and TNF) that are associated with cognitive dysfunction (Ja ¨rvinen
et al, 1996). Retrospective investigations examining the neurotoxic
effects of chemotherapy on neurocognitive function in breast
cancer patients have not found differences between women who
either received or did not receive TAM subsequent to chemother-
apy (Schagen et al, 1999). However, PET imaging has demon-
strated greater prefrontal hypometabolism in women with
treatment histories that included both chemotherapy and TAM
compared to women treated with chemotherapy alone (Silverman
et al, 2003).
Paganini-Hill and Clark (2000) reported that women who
previously used TAM performed similarly on a neurocognitive
screen when compared to a group of breast cancer survivors never
exposed to TAM, while current TAM users had slightly less
complex narrative writing samples. However, this methodology is
ineffective for examining cognitive function and potentially yields
useless data. We have been engaged in a prospective, longitudinal
trial utilising a comprehensive neuropsychological assessment to
determine the neurocognitive and neurobehavioural sequelae
associated with adjuvant TAM therapy. Our unpublished pre-
liminary findings suggest that a subgroup of women taking TAM
experience a significant neurotoxicity consisting of memory,
executive, and motor dysfunction associated with increased
affective distress, decreased QOL, and diminished ability to
maintain productive activities. This trial is also examining
potential mechanisms responsible for this neurotoxicity including
alterations in circulating levels of proinflammatory cytokines as
well as fluctuations in stress and sex hormones. A number of other
SERMs and aromotase inhibitors are currently being investigated
for clinical use and may also be associated with similar reports of
neurotoxicity.
Testosterone supplementation has been reported to enhance
cognitive function in healthy older men (Cherrier et al, 2001). The
hippocampus contains testosterone receptors as well as estradiol
receptors, and thus it is unclear if these beneficial effects arise
through the androgen receptors or via aromitisation to estradiol,
or both. Hormonal challenges in men via administration of
luteinising hormone-releasing hormone agonists, such as leupro-
lide or goserelin, also may adversely affect hippocampal function
through these hormonal channels. There are inconsistent findings
with regard to the safety profile of androgen ablating agents, with
some authors reporting no evidence of neurocognitive decline or
neurobehavioural dysfunction (Salminen et al, 2003), and others
finding impaired memory, attention, and executive function
(Green et al, 2002).
ADJUVANT MEDICATIONS AND MEDICAL
COMPLICATIONS
Priniciple: The assessment of cognitive dysfunction secondary to
cancer treatment is complicated by the use of supportive medica-
tions (e.g. steroids, immunosuppressive agents, anticonvulsants)
that can alter cognitive function.
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adjuvant medications such as steroids, anticonvulsants, and pain
medications may also cause neurocognitive and neurobehavioural
symptoms. The use of glucocorticoids is ubiquitous and is
associated with a 5–50% incidence of steroid-induced psychiatric
syndromes including euphoria, mania, insomnia, restlessness, and
increased motor activity. Glucocorticoids have been implicated in
the development of memory dysfunction across a variety of
conditions including chronic stress and post-traumatic stress
disorder. Certain anticonvulsants (e.g. topiramate, phenobarbital)
are also known to have adverse neurocognitive effects. Both
seizure frequency and the use of anticonvulsants have been
demonstrated to adversely impact neurocognitive function in
brain tumour patients (Klein et al, 2003). Pharmacologic inter-
vention for symptoms of pain may cause sedation and associated
diminution of neurocognitive function.
Abnormalities in endocrinologic function secondary to hy-
pothalamic/pituitary injury are very common following radio-
therapy. Thyroid dysfunction, loss of libido, and erectile
dysfunction are present in a large proportion of patients.
Endocrinologic replacement therapy has the potential to improve
neurocognitive and neurobehavioural function in patients who
have abnormal hormone levels. Anaemia is a side effect of some
chemotherapeutic regimens that is associated with both fatigue
and neurocognitive dysfunction. Epoetin alpha therapy has been
found to minimise neurocognitive decline in breast cancer patients
receiving anthracycline-based chemotherapies relative to placebo
(O’Shaughnessy, 2002). The aetiology of cancer-related fatigue is
likely multifactorial and includes anaemia, cachexia, systemic
illness, pain, and medications (Kurzrock, 2001). Both peripheral
and central factors associated with cytokine production may be
involved in the development and maintenance of this state.
NEUROPSYCHOLOGICAL ASSESSMENT
Although the importance of cognitive evaluations in the care of
cancer patients and in clinical cancer trials is receiving greater
recognition, assessment methods remain less than optimal in most
cases. Cognitive assessment is a complex undertaking that requires
diverse skills. Although the administration of tests is a relatively
simple endeavour, interpretation of test scores relies heavily on the
clinician’s interviewing skills, appreciation of social and cultural
factors, understanding of test construction and psychometrics,
psychodiagnostic skills, and knowledge of the human nervous
system (see Figure 1).
The contemporary scientific literature is cluttered with poorly
designed studies that may lead investigators and the readership to
incorrect conclusions. Clinicians and researchers must keep a few
basic principles in mind when developing a plan for assessment.
First, test selection will vary depending on the question under
consideration. Second, the measures chosen should have alternate
forms or be relatively resistant to practice effects, characteristics
that are especially important if one plans to test patients
repeatedly. Third, selected measures should be psychometrically
sound, with established reliability and validity, and appropriate
normative studies. Finally, it is important to select measures that
are sensitive to subtle changes in cognitive function often
experienced by patients with cancer. Attention, processing speed,
learning/memory functions, and motor skills are particularly
vulnerable and should be carefully evaluated for signs of
dysfunction.
SUMMARY
Cancer is becoming a chronic illness, requiring on-going symptom
assessment and intervention. The number of long-term cancer
survivors will continue to increase as will the number of survivors
with neurocognitive and/or neurobehavioural impairment. It is
important to note that treatment-related cognitive decline is not
universal among cancer patients. Some individuals are able to
tolerate treatment with little physical discomfort and no obvious
neurocognitive impairments, while others will develop significant
toxicities that seriously compromise their perceived quality of life
and prevent them from resuming their usual social and occupa-
tional roles. However, any adverse effects of cancer treatment must
always be considered in the light of potential therapeutic benefits.
The nature of neurocognitive and neurobehavioural dysfunction
is yet to be fully characterised. Methodological challenges have
Pesticides
(treatment factors)
e.g. Primary and adjuvant therapies, 
medications for symptom control, 
complementary therapies
Soil
(patient factors)
e.g. Age, education, medical history, 
current symptoms, behavioural observations
Test selection
e.g. Psychometric issues, relevance and 
compatibility with the purpose of the assessment
Interpretation, prognostication and treatment
Integration of these sources of information requires understanding of human 
behaviour, CNS function, disease process, treatment effects, test pattern analysis,
and knowledge of cognitive/behavioural/pharmacological interventions 
Seed
(disease factors)
e.g. Diagnosis, location, tumour burden,
disease course
Figure 1 Considerations for the cognitive assessment of the oncology patient.
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saturate the existing literature. Increased inclusion of comprehen-
sive neuropsychological evaluations in clinical research will further
our understanding of the nature, severity, and processes under-
lying neurocognitive dysfunction in the patient with cancer.
Multidisciplinary investigations are essential. Utilising advances
in neuropsychology, cognitive neuroscience, genomics, proteo-
nomics, molecular epidemiology, functional neuroimaging, neu-
roimmunology, and traditional oncologic disciplines will
ultimately contribute to understanding the relationships between
disease, treatment, and patient factors in the manifestation of
altered neurocognitive and neurobehavioural function. These
multidisciplinary investigations will identify which agents are
most neurotoxic in the context of different treatment regimens, the
course of the neurocognitive and neurobehavioural dysfunction,
the cognitive and neurobehavioural domains most affected, the
mechanisms for these effects, the host risk factors that create a
diathesis for the expression of this neurotoxicity, and which
neuroprotective or rehabilitative therapies may be most efficacious
in preventing or treating these adverse symptoms.
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